Volume 7.45 | Nov 19

Cord Blood News 7.45 November 19, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Umbilical Cord Blood-Derived T Regulatory Cells to Prevent GVHD: Kinetics, Toxicity Profile and Clinical Effect
Researchers studied the safety and clinical outcomes of patients treated with umbilical cord blood derived regulatory T cells that expanded in cultures stimulated with K562 cells modified to express the high affinity Fc receptor and CD86, the natural ligand of CD28. [Blood] Abstract
SmartDish™ with STEMgrid™-6 for Accurate Counting of Hematopoietic CFU Assays
PUBLICATIONS (Ranked by impact factor of the journal)
Senescence Associated MCP-1 Secretion Is Dependent on a Decline in BMI1 in Human Mesenchymal Stromal Cells
The authors showed that positive feedback between senescence-associated secretory phenotype and inherent senescence processes plays a crucial role in the senescence of umbilical cord blood-derived mesenchymal stromal cells. [Antioxid Redox Signal] Abstract

Injection of Human Cord Blood Cells with Hyaluronan Improves Postinfarction Cardiac Repair in Pigs
Researchers tested whether injection of human cord blood mononuclear cells combined with hyaluronan hydrogel improves cell therapy efficacy in a pig myocardial infarction model. [Stem Cells Transl Med] Abstract

Role of Keratinocyte Growth Factor in the Differentiation of Sweat Gland-Like Cells From Human Umbilical Cord-Derived Mesenchymal Stem Cells
Investigators demonstrated that keratinocyte growth factor is a critical growth factor for sweat gland-like cells (SGC) differentiation from human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and the differentiated SGC from hUC-MSCs may have a potential therapeutic application for regeneration of destroyed sweat-glands and injured skin. [Stem Cells Transl Med] Abstract

The Efficacy of Extraembryonic Stem Cells in Improving Blood Flow within Animal Models of Lower Limb Ischemia
Scientists investigated the efficacy of extraembryonic tissue-derived stem cell in improving blood flow within animal models of hindlimb ischemia. [Heart] Abstract

Myeloablative, but Not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in AML
Scientists evaluated the effect of flow cytometry status on outcomes of allogeneic hematopoietic cell transplantation for acute myeloid leukemia (AML) after either myeloablative conditioning myeloablative conditioning or reduced-intensity conditioning regimens. The allografts included 130 umbilical cord blood and 73 sibling donors. [Biol Blood Marrow Transplant] Abstract

Immunoregulatory Effects on T lymphocytes by Human Mesenchymal Stromal Cells Isolated from Bone Marrow, Amniotic Fluid and Placenta
Mesenchymal stromal cells (MSCs) isolated from amniotic fluid and placenta were compared with bone marrow-MSCs. Their immunomodulant properties were studied on total activated T-cells with phytoemoagglutin. [Exp Hematol] Abstract

Get More of the Cells You Need with StemSpan™ Myeloid Expansion Supplement and StemSpan™ SFEM
A Risk-Adapted Approach to Acute GVHD Treatment: Are We There Yet?
Acute GVHD is an immunologic complication of allogeneic hematopoietic cell transplantation that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials has arrived. The authors summarize recent refinements to these models. [Bone Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
CytomX and MD Anderson Cancer Center Enter into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies
CytomX Therapeutics entered into a collaboration with the University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer cell therapies. MD Anderson will leverage its expertise in developing allogeneic umbilical cord blood and peripheral blood derived NK-cell therapies and combine it with CytomX’s Probody technology to address new targets for this novel modality in cancer immunotherapy. [CytomX Therapeutics] Press Release

ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program
ImmunoCellular Therapeutics, Ltd. announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. The ultimate goal of this work is to enable a clinical program based on hematopoietic stem cells that are isolated from the patient, engineered in the lab and then returned to the patient to create a population of antigen-specific killer T cells that target and kill the tumor. [ImmunoCellular Therapeutics, Ltd.] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cancer as an Evolving and Systemic Disease
March 12-15, 2016
New York City, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Research Scientist – Immunotherapy Group (The Anthony Nolan Trust)

Faculty Positions – Regenerative Medicine for Organ Regeneration or Transplantation (The University of Texas Medical School at Houston)

Postdoctoral Fellow – Leukemia Research (City of Hope)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Faculty Member – Hematopoietic Cell Transplant (Fred Hutchinson Cancer Research Center)

Hematopoietic Stem Cell Biologist (Mayo Clinic)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us